Newsbenzinga
Cardinal Health Says It Now Exclusively Serves Nearly Half The Cell-And-Gene Therapy Market
· Published
Article summary
CAH stock hits new 52-week high as Cardinal Health beats Q4 earnings, boosts FY27 outlook, and approves a $5B buyback expansion.
An excerpt from the original article.
Comments —
Loading comments…